Evidence map›Paper›PMID 31646997›Full record

ArticleBMC cancer2019

Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.

Ann-Kathrin Stoppek, Sied Kebir, Andreas Junker, Kathy Keyvani, Stefan Zülow, Lazaros Lazaridis, Teresa Schmidt, Daniela Pierscianek, Martin Stuschke, Ulrich Sure and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Ann-Kathrin StoppekDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Sied KebirDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Andreas JunkerInstitute of Neuropathology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Kathy KeyvaniInstitute of Neuropathology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Stefan ZülowInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Lazaros LazaridisDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Teresa SchmidtDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Daniela PierscianekWest German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Martin StuschkeDepartment of Radiotherapy, University Hospital Essen, Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Ulrich SureWest German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Christoph KleinschnitzDepartment of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Björn SchefflerDKFZ Division of Translational Neurooncology at the West German Cancer Center (WTZ); German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Lisa ZimmerWest German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Martin GlasDivision of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. Martin.Glas@uk-essen.de.ORCID http://orcid.org/0000-0003-3167-3403
Essen University Hospital · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeptomeningeal metastasis (LM) is a predominantly late stage, devastating complication of a variety of malignant solid tumors. Diagnosis relies predominantly on neurological, radiographic, and cerebrospinal fluid (CSF) assessments. Recently, liquid biopsy tests derived from CSF has shown to be a feasible, noninvasive promising approach to tumor molecular profiling for proper brain cancer diagnostic treatment, thereby providing an opportunity for CSF-based personalized medicine. However, LM is typically misleadingly assumed to originate from only one primary tumor type. CASE PRESENTATION: In this case report, we provide first evidence of the co-occurrence of LM originating from more than one primary tumor types. DISCUSSION AND

conclusionsBased on this patient case profile, the co-occurrence of LM from two or more primary tumor types should be accounted for when deriving diagnostic conclusions from liquid biopsy tests.

Indexed as

Adenocarcinoma of LungAgedFatal OutcomeFemaleHumansLiquid BiopsyLung NeoplasmsMelanomaMeningeal NeoplasmsAdenocarcinomaLeptomeningeal metastasisMelanomaSimultaneous

Identifiers

PMID31646997
PMCPMC6813083
OpenAlexW2981775335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.